NTLA
Price
$10.00Alerts
Change
+$0.48 (+5.04%)
Updated
Nov 20 closing price
Capitalization
1.59B
96 days until earnings call
Intraday BUY SELL Signals
PRME
Price
$3.55Alerts
Change
-$0.29 (-7.55%)
Updated
Nov 20 closing price
Capitalization
843.4M
Intraday BUY SELL Signals
Interact to see
Advertisement

NTLA vs PRME

NTLA vs PRME Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NTLA vs. PRME commentary
Nov 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and PRME is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for NTLA with price predictions
Nov 20, 2026

Momentum Indicator for NTLA turns negative, indicating new downward trend

NTLA saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In 86 of the 94 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for NTLA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 42 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

NTLA moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 20 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in 206 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

NTLA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.186) is normal, around the industry mean (3.596). P/E Ratio (-3.398) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for PRME with price predictions
Nov 20, 2026

PRME in downward trend: price dove below 50-day moving average on November 20, 2026

PRME moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend. In 32 of 34 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PRME moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 15 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRME as a result. In 60 of 67 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for PRME turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 31 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

PRME broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 50-day moving average for PRME moved above the 200-day moving average on October 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +11.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in 159 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 95 of 114 cases where PRME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.422) is normal, around the industry mean (3.596). P/E Ratio (-4.429) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. PRME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
NTLA vs PRME: Fundamental Ratings
NTLA
PRME
OUTLOOK RATING
1..100
7271
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
6442
P/E GROWTH RATING
1..100
5291
SEASONALITY SCORE
1..100
1450

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (27) in the null industry is in the same range as NTLA (36) in the Biotechnology industry. This means that PRME’s stock grew similarly to NTLA’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to NTLA’s over the last 12 months.

PRME's SMR Rating (95) in the null industry is in the same range as NTLA (98) in the Biotechnology industry. This means that PRME’s stock grew similarly to NTLA’s over the last 12 months.

PRME's Price Growth Rating (42) in the null industry is in the same range as NTLA (64) in the Biotechnology industry. This means that PRME’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's P/E Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for PRME (91) in the null industry. This means that NTLA’s stock grew somewhat faster than PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAPRME
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 13 days ago
79%
Bullish Trend 18 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
83%
COMPARISON
Comparison
Nov 21, 2026
Stock price -- (NTLA: $10.00 vs. PRME: $3.55)
Brand notoriety: NTLA and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 296% vs. PRME: 126%
Market capitalization -- NTLA: $1.59B vs. PRME: $843.4M
NTLA [@Biotechnology] is valued at $1.59B. PRME’s [@Biotechnology] market capitalization is $843.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 0 FA rating(s) are green while PRME’s FA Score has 1 green FA rating(s).

  • NTLA’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 1 green, 4 red.
According to our system of comparison, PRME is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 3 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 3 bullish, 5 bearish.
  • PRME’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both NTLA and PRME are a bad buy in the short-term.

Price Growth

NTLA (@Biotechnology) experienced а +3.09% price change this week, while PRME (@Biotechnology) price change was -16.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 25, 2027.

Industries' Descriptions

@Biotechnology (-11.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-7.55%
CRSP - PRME
65%
Loosely correlated
+0.44%
BEAM - PRME
63%
Loosely correlated
-0.19%
NTLA - PRME
62%
Loosely correlated
+5.04%
EDIT - PRME
61%
Loosely correlated
-4.09%
RXRX - PRME
61%
Loosely correlated
-9.93%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SPPL2.74-0.01
-0.36%
Simpple Ltd
OSBC24.17-0.19
-0.78%
Old Second Bancorp
WH77.10-1.61
-2.05%
Wyndham Hotels & Resorts
PROF6.38-0.21
-3.19%
Profound Medical Corp
INTU270.44-39.58
-12.77%
Intuit